サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1544108

プライマリーセルの世界市場

Primary Cells

出版日
ページ情報
英文 184 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
プライマリーセルの世界市場
出版日: 2024年08月29日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

プライマリーセルの世界市場は2030年までに18億米ドルに達する見込み

2023年に11億米ドルと推定されるプライマリーセルの世界市場は、2030年には18億米ドルに達し、分析期間2023-2030年のCAGRは7.1%で成長すると予測されます。本レポートで分析されているセグメントの1つであるヒトプライマリーセルは、CAGR 7.4％を記録し、分析期間終了時には14億米ドルに達すると予測されています。動物プライマリーセル分野の成長率は、分析期間中CAGR 5.7％と推定されます。

米国市場は2億9,820万米ドル、中国はCAGR 6.7％で成長すると予測される

米国のプライマリーセル市場は、2023年に2億9,820万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 6.7%で推移し、2030年には2億7,260万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.6%と5.7%と予測されています。欧州では、ドイツがCAGR 5.8%で成長すると予測されています。

世界のプライマリーセル市場- 主要動向と促進要因まとめ

プライマリーセル：バイオメディカル研究と医薬品開発に不可欠なツール

プライマリーセルは、生きた組織から直接採取され、試験管内で培養された細胞で、元の組織の生理学的特徴や機能の多くを保持しています。不死化細胞株とは異なり、プライマリーセルは無限に増殖するように改変されているため、寿命が限られており、体内の細胞の挙動を忠実に模倣しています。これらの細胞は、生物医学研究、毒物学研究、医薬品開発において不可欠なツールであり、正常および病的細胞機能の研究、潜在的な医薬品候補のスクリーニング、疾患のモデルとして使用されます。プライマリーセルは、血液、皮膚、肝臓、脳など様々な組織に由来し、特定の臓器やシステムのモデルを作るために培養することができます。細胞株よりも正確で適切なデータを提供できるため、複雑な生物学的プロセスを理解し、効果的な治療法を開発しようとする研究者にとって、プライマリーセルは貴重な存在となっています。

技術の進歩はプライマリーセルとその応用をどのように強化していますか？

技術の進歩は、プライマリーセルの分離、培養、応用を著しく改善し、幅広い研究開発に利用しやすく、有用なものにしています。蛍光活性化セルソーティング（FACS）や磁気活性化セルソーティング（MACS）のような細胞分離技術の革新は、特定の特性を持つプライマリーセルの純粋な集団を得る能力を高め、実験結果の信頼性と再現性を向上させました。高度な培養培地とサプリメントの開発により、試験管内でのプライマリーセルの寿命が延び、より長時間の実験とより包括的な研究が可能になりました。さらに、3D細胞培養技術と臓器オンチップシステムの統合により、プライマリーセルを用いたより生理学的に適切なモデルの作製が可能となり、組織機能や疾患メカニズムに関するより深い洞察が得られるようになりました。このような技術的改良により、プライマリーセルの用途と利点は拡大し、最先端の生物医学研究や創薬に不可欠なツールとなっています。

プライマリーセルの主な用途と利点は？

プライマリーセルは、様々な研究開発アプリケーションに使用され、科学的研究の正確性と妥当性を高める数多くの利点を提供します。医薬品開発では、プライマリーセルは潜在的な薬剤候補の有効性や毒性をスクリーニングするために使用され、薬剤が人体内でどのように作用するかについて、より信頼性の高いデータを提供します。疾患モデリングでは、プライマリーセルはがん、神経変性疾患、循環器疾患などの試験管内疾患モデルの作成に使用され、研究者は制御された環境で疾患メカニズムを研究し、潜在的な治療法をテストすることができます。個別化医療では、個々の患者から得られたプライマリーセルは、カスタマイズされた治療を開発し、特定の薬剤に対する患者の反応を予測するために使用されます。プライマリーセルを使用する主な利点は、in vivoの状態を忠実に模倣する能力、細胞株よりも正確なデータを提供する能力、複雑な生物学的プロセスに対する洞察を提供する能力などです。プライマリーセルは、適切で信頼性の高いモデルシステムを提供することで、生物医学研究の進展と新しい治療法の開発に重要な役割を果たしています。

プライマリーセル市場の成長を促進する要因は？

プライマリーセル市場の成長は、いくつかの要因によって牽引されています。プライマリーセルは細胞株と比較してin vivoの状態をより正確に表現できるため、生物医学研究や医薬品開発において、より生理学的に関連性の高いモデルへの需要が高まっていることが重要な原動力となっています。プライマリーセルの分離、培養、応用を改善する技術の進歩も、市場の成長を後押ししています。個別化医療への注目の高まりと、医薬品開発における患者特異的モデルの必要性が、プライマリーセルの需要をさらに押し上げています。さらに、がん、免疫学、神経科学などの分野における研究活動の拡大も、複雑な生物学的システムの研究に不可欠なプライマリーセルの市場成長に寄与しています。市販のサプライヤーから高品質のプライマリーセルが入手できるようになり、高度な培養システムの使用が増加していることも、市場の拡大を後押ししています。これらの要因は、細胞培養技術における継続的な技術革新と相まって、プライマリーセル市場の持続的成長を後押ししています。

調査対象企業の例（全22社）

  • Allcells LLC
  • American Type Culture Collection（ATCC）
  • Axol Bioscience Ltd.
  • Cell Biologics, Inc.
  • Lonza Group AG
  • Merck KgaA
  • Promocell GmbH
  • Thermo Fisher Scientific, Inc.
  • Zenbio, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP14203

Global Primary Cells Market to Reach US$1.8 Billion by 2030

The global market for Primary Cells estimated at US$1.1 Billion in the year 2023, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2023-2030. Human Primary Cells, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Animal Primary Cells segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$298.2 Million While China is Forecast to Grow at 6.7% CAGR

The Primary Cells market in the U.S. is estimated at US$298.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$272.6 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.6% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Primary Cells Market - Key Trends and Drivers Summarized

Primary Cells: Essential Tools for Biomedical Research and Drug Development

Primary cells are cells taken directly from living tissue and cultured in vitro, retaining many of the physiological characteristics and functions of the original tissue. Unlike immortalized cell lines, which are modified to proliferate indefinitely, primary cells have a limited lifespan and closely mimic the behavior of cells in the body. These cells are essential tools in biomedical research, toxicology studies, and drug development, where they are used to study normal and pathological cell functions, screen potential drug candidates, and model diseases. Primary cells are derived from various tissues, including blood, skin, liver, and brain, and can be cultured to create models of specific organs or systems. Their ability to provide more accurate and relevant data than cell lines makes primary cells invaluable for researchers seeking to understand complex biological processes and develop effective therapies.

How Are Technological Advancements Enhancing Primary Cells and Their Applications?

Technological advancements have significantly improved the isolation, culture, and application of primary cells, making them more accessible and useful for a wide range of research and development activities. Innovations in cell isolation techniques, such as fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS), have enhanced the ability to obtain pure populations of primary cells with specific characteristics, improving the reliability and reproducibility of experimental results. The development of advanced culture media and supplements has extended the lifespan of primary cells in vitro, allowing for longer experiments and more comprehensive studies. Additionally, the integration of 3D cell culture technologies and organ-on-a-chip systems has enabled the creation of more physiologically relevant models using primary cells, providing better insights into tissue function and disease mechanisms. These technological improvements have expanded the applications and benefits of primary cells, making them essential tools in cutting-edge biomedical research and drug discovery.

What Are the Key Applications and Benefits of Primary Cells?

Primary cells are used in a variety of research and development applications, offering numerous benefits that enhance the accuracy and relevance of scientific studies. In drug development, primary cells are used to screen potential drug candidates for efficacy and toxicity, providing more reliable data on how a drug will behave in the human body. In disease modeling, primary cells are used to create in vitro models of diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions, allowing researchers to study disease mechanisms and test potential therapies in a controlled environment. In personalized medicine, primary cells derived from individual patients are used to develop customized treatments and predict patient responses to specific drugs. The primary benefits of using primary cells include their ability to closely mimic in vivo conditions, provide more accurate data than cell lines, and offer insights into complex biological processes. By providing a relevant and reliable model system, primary cells play a critical role in advancing biomedical research and developing new therapies.

What Factors Are Driving the Growth in the Primary Cells Market?

The growth in the primary cells market is driven by several factors. The increasing demand for more physiologically relevant models in biomedical research and drug development is a significant driver, as primary cells offer a more accurate representation of in vivo conditions compared to cell lines. Technological advancements that improve the isolation, culture, and application of primary cells are also propelling market growth. The rising focus on personalized medicine and the need for patient-specific models in drug development are further boosting demand for primary cells. Additionally, the expansion of research activities in fields such as cancer, immunology, and neuroscience is contributing to market growth, as primary cells are essential for studying these complex biological systems. The growing availability of high-quality primary cells from commercial suppliers, coupled with the increasing use of advanced culture systems, is also supporting market expansion. These factors, combined with continuous innovation in cell culture technologies, are driving the sustained growth of the primary cells market.

Select Competitors (Total 22 Featured) -

  • Allcells LLC
  • American Type Culture Collection (ATCC)
  • Axol Bioscience Ltd.
  • Cell Biologics, Inc.
  • Lonza Group AG
  • Merck KgaA
  • Promocell GmbH
  • Thermo Fisher Scientific, Inc.
  • Zenbio, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Primary Cells - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in 3D Cell Culture Technology Propel Growth in Primary Cells Market
    • Increasing Investment in Stem Cell Research Expands Addressable Market Opportunity
    • CRISPR-Cas9 Technology Adoption Strengthens Business Case for Primary Cells
    • Growing Focus on Regenerative Medicine Drives Demand for Animal Primary Cells
    • Advancements in Biopharmaceuticals Accelerate Demand for Human Primary Cells
    • Expansion of Life Science Research Companies Generates Demand for High-Quality Primary Cells
    • Innovations in Cell Preservation Techniques Strengthen Business Case for Primary Cell Usage
    • Emergence of Organoid Technology Drives Adoption of Primary Cells in Cancer Research
    • Rising Prevalence of Chronic Diseases Expands Addressable Market for Primary Cells
    • Increasing Use of Primary Cells in Toxicology Testing Expands Market Opportunities
    • Growing Complexity of Drug Discovery and Development Generates Demand for Primary Cells
    • Technological Integration with High-Throughput Screening Expands Market Opportunity
    • Advancements in Immuno-oncology Research Propel Growth in Primary Cells Market
    • Adoption of Next-Generation Sequencing (NGS) Techniques in Primary Cell Research Expands Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Primary Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Primary Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Primary Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Human Primary Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Human Primary Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Human Primary Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Animal Primary Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Animal Primary Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Animal Primary Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Life Science Research Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Life Science Research Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Life Science Research Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Primary Cells Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Primary Cells Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Primary Cells by Type - Human Primary Cells and Animal Primary Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Primary Cells by Type - Human Primary Cells and Animal Primary Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Primary Cells by Type - Percentage Breakdown of Value Sales for Human Primary Cells and Animal Primary Cells for the Years 2014, 2024 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Primary Cells by End-Use - Life Science Research Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Primary Cells by End-Use - Life Science Research Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Primary Cells by End-Use - Percentage Breakdown of Value Sales for Life Science Research Companies and Research Institutes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Primary Cells by Type - Human Primary Cells and Animal Primary Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Primary Cells by Type - Human Primary Cells and Animal Primary Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Primary Cells by Type - Percentage Breakdown of Value Sales for Human Primary Cells and Animal Primary Cells for the Years 2014, 2024 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Primary Cells by End-Use - Life Science Research Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Primary Cells by End-Use - Life Science Research Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Primary Cells by End-Use - Percentage Breakdown of Value Sales for Life Science Research Companies and Research Institutes for the Years 2014, 2024 & 2030
  • JAPAN
    • Primary Cells Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Primary Cells by Type - Human Primary Cells and Animal Primary Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Primary Cells by Type - Human Primary Cells and Animal Primary Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Primary Cells by Type - Percentage Breakdown of Value Sales for Human Primary Cells and Animal Primary Cells for the Years 2014, 2024 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Primary Cells by End-Use - Life Science Research Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Primary Cells by End-Use - Life Science Research Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Primary Cells by End-Use - Percentage Breakdown of Value Sales for Life Science Research Companies and Research Institutes for the Years 2014, 2024 & 2030
  • CHINA
    • Primary Cells Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Primary Cells by Type - Human Primary Cells and Animal Primary Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Primary Cells by Type - Human Primary Cells and Animal Primary Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: China 16-Year Perspective for Primary Cells by Type - Percentage Breakdown of Value Sales for Human Primary Cells and Animal Primary Cells for the Years 2014, 2024 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Primary Cells by End-Use - Life Science Research Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Primary Cells by End-Use - Life Science Research Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Primary Cells by End-Use - Percentage Breakdown of Value Sales for Life Science Research Companies and Research Institutes for the Years 2014, 2024 & 2030
  • EUROPE
    • Primary Cells Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Primary Cells by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Primary Cells by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Primary Cells by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Primary Cells by Type - Human Primary Cells and Animal Primary Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Primary Cells by Type - Human Primary Cells and Animal Primary Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Primary Cells by Type - Percentage Breakdown of Value Sales for Human Primary Cells and Animal Primary Cells for the Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Primary Cells by End-Use - Life Science Research Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Primary Cells by End-Use - Life Science Research Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Primary Cells by End-Use - Percentage Breakdown of Value Sales for Life Science Research Companies and Research Institutes for the Years 2014, 2024 & 2030
  • FRANCE
    • Primary Cells Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Primary Cells by Type - Human Primary Cells and Animal Primary Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Primary Cells by Type - Human Primary Cells and Animal Primary Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: France 16-Year Perspective for Primary Cells by Type - Percentage Breakdown of Value Sales for Human Primary Cells and Animal Primary Cells for the Years 2014, 2024 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Primary Cells by End-Use - Life Science Research Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Primary Cells by End-Use - Life Science Research Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Primary Cells by End-Use - Percentage Breakdown of Value Sales for Life Science Research Companies and Research Institutes for the Years 2014, 2024 & 2030
  • GERMANY
    • Primary Cells Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Primary Cells by Type - Human Primary Cells and Animal Primary Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Primary Cells by Type - Human Primary Cells and Animal Primary Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Primary Cells by Type - Percentage Breakdown of Value Sales for Human Primary Cells and Animal Primary Cells for the Years 2014, 2024 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Primary Cells by End-Use - Life Science Research Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Primary Cells by End-Use - Life Science Research Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Primary Cells by End-Use - Percentage Breakdown of Value Sales for Life Science Research Companies and Research Institutes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Primary Cells by Type - Human Primary Cells and Animal Primary Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Primary Cells by Type - Human Primary Cells and Animal Primary Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Primary Cells by Type - Percentage Breakdown of Value Sales for Human Primary Cells and Animal Primary Cells for the Years 2014, 2024 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Primary Cells by End-Use - Life Science Research Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Primary Cells by End-Use - Life Science Research Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Primary Cells by End-Use - Percentage Breakdown of Value Sales for Life Science Research Companies and Research Institutes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Primary Cells Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Primary Cells by Type - Human Primary Cells and Animal Primary Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Primary Cells by Type - Human Primary Cells and Animal Primary Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Primary Cells by Type - Percentage Breakdown of Value Sales for Human Primary Cells and Animal Primary Cells for the Years 2014, 2024 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Primary Cells by End-Use - Life Science Research Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Primary Cells by End-Use - Life Science Research Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Primary Cells by End-Use - Percentage Breakdown of Value Sales for Life Science Research Companies and Research Institutes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Primary Cells by Type - Human Primary Cells and Animal Primary Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of Europe Historic Review for Primary Cells by Type - Human Primary Cells and Animal Primary Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Rest of Europe 16-Year Perspective for Primary Cells by Type - Percentage Breakdown of Value Sales for Human Primary Cells and Animal Primary Cells for the Years 2014, 2024 & 2030
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Primary Cells by End-Use - Life Science Research Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Primary Cells by End-Use - Life Science Research Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Primary Cells by End-Use - Percentage Breakdown of Value Sales for Life Science Research Companies and Research Institutes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Primary Cells Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Primary Cells by Type - Human Primary Cells and Animal Primary Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific Historic Review for Primary Cells by Type - Human Primary Cells and Animal Primary Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Asia-Pacific 16-Year Perspective for Primary Cells by Type - Percentage Breakdown of Value Sales for Human Primary Cells and Animal Primary Cells for the Years 2014, 2024 & 2030
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Primary Cells by End-Use - Life Science Research Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Primary Cells by End-Use - Life Science Research Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Primary Cells by End-Use - Percentage Breakdown of Value Sales for Life Science Research Companies and Research Institutes for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Primary Cells by Type - Human Primary Cells and Animal Primary Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of World Historic Review for Primary Cells by Type - Human Primary Cells and Animal Primary Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of World 16-Year Perspective for Primary Cells by Type - Percentage Breakdown of Value Sales for Human Primary Cells and Animal Primary Cells for the Years 2014, 2024 & 2030
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Primary Cells by End-Use - Life Science Research Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Primary Cells by End-Use - Life Science Research Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Primary Cells by End-Use - Percentage Breakdown of Value Sales for Life Science Research Companies and Research Institutes for the Years 2014, 2024 & 2030

IV. COMPETITION